REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Regenxbio (RGNX) Misses Q1 EPS by 21c, Revenues Miss
May 7, 2020 5:36 PM EDTRegenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.08), $0.21 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $17.64 million versus the consensus estimate of $18.45 million.
"Our overall focus at REGENXBIO during the COVID-19... More
